Variant · Insertion

EGFR D770_N771insSVD

CI-VAR-00000545Explore in graph →NP_005219.2:p.Asp770_Asn771insSerValAspNM_005228.5:c.2303_2311dupClinVar 45253 CIViC 1445 rs397517109

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma3
EGFR D770_N771insSVD	Erlotinib	Predictive	C	Does Not Support Sensitivity Response	3	submitted	EID5941 2 patients with EGFR D770_N771insSVD positive lung adenocarcinoma were treated with erlotinib tyrosine kinase inhibitor as first line treatment. A 66 year old female never smoker had stable disease a… (full text at CIViC) PMID 24353160 · Yasuda et al., 2013 · Open in CIViC	civic
EGFR D770_N771insSVD	Erlotinib	Predictive	D	Supports Resistance	—	accepted	EID4275 In an in vitro study, a Ba/F3 cell line expressing EGFR D770_N771insSVD demonstrated reduced sensitivity to erlotinib treatment (IC50=3.187�M), comparable to Ba/F3 cells expressing EGFR L858R and T790… (full text at CIViC) PMID 24353160 · Yasuda et al., 2013 · Open in CIViC

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
45253	drug response	criteria provided, single submitter	1	Non-small cell lung carcinoma; Tyrosine kinase inhibitor response; Lung adenocarcinoma	somatic	2	Jun 01, 2012	clinvar